Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Several studies in recent times have linked gut microbiome (GM) diversity to the pathogenesis of cancer and its role in disease progression through immune response, inflammation and metabolism modulation. This study focused on the use of network analysis and weighted gene co-expression network analysis (WGCNA) to identify the biological interaction between the gut ecosystem and its metabolites that could impact the immunotherapy response in non-small cell lung cancer (NSCLC) patients undergoing second-line treatment with anti-PD1. Metabolomic data were merged with operational taxonomic units (OTUs) from 16S RNA-targeted metagenomics and classified by chemometric models. The traits considered for the analyses were: (i) condition: disease or control (CTRLs), and (ii) treatment: responder (R) or non-responder (NR). Network analysis indicated that indole and its derivatives, aldehydes and alcohols could play a signaling role in GM functionality. WGCNA generated, instead, strong correlations between short-chain fatty acids (SCFAs) and a healthy GM. Furthermore, commensal bacteria such as Akkermansia muciniphila, Rikenellaceae, Bacteroides, Peptostreptococcaceae, Mogibacteriaceae and Clostridiaceae were found to be more abundant in CTRLs than in NSCLC patients. Our preliminary study demonstrates that the discovery of microbiota-linked biomarkers could provide an indication on the road towards personalized management of NSCLC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 1×
“In order to adjust the statistical tests for multiple comparisons, the FDR method [50] was used for p-values estimation.”
MethodWGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Fast unfolding of communities in large networks
Blondel, V. D., Guillaume, J.-L., Lambiotte, R., & Lefebvre, E. (2008) · Journal of Statistical Mechanics: Theory and Experiment · doi:10.1088/1742-5468/2008/10/p10008 · Cited by 21,424
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · cited 2×
“Chen and Mellman [4] described the significance of the GM in anti-cancer response via the concept of a cancer immunity cycle.”
BackgroundCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
A General Framework for Weighted Gene Co-Expression Network Analysis
Zhang, B., & Horvath, S. (2005) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1128 · Cited by 5,684 · cited 2×
“WGCNA is the most commonly employed method to construct gene co-expression networks, identifying modules and detecting the central or hub genes within the modules [22,23].”
MethodGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · cited 1×
“Recently, several studies suggested the role of the GM in modulating patient response to immunotherapy in cancer [16,17,36,62,63].”
BackgroundCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“Landmark studies in animal models revealed that gut microbes can directly affect the response to immunotherapy [10,11].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Landmark studies in animal models revealed that gut microbes can directly affect the response to immunotherapy [10,11].”
BackgroundDefining and identifying communities in networks
Radicchi, F., Castellano, C., Cecconi, F., Loreto, V., & Parisi, D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400054101 · Cited by 2,450 · cited 2×
“Communities are a subset of nodes within a network that have dense internal connections, compared to the connections with the rest of the network [55].”
BackgroundRole of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256 · cited 1×
“The gut microbiota (GM) plays a fundamental role in the functional framework of the host immune system and any changes in diet, overuse of antibiotics, xenobiotics and gastrointestinal (GI) tract infections can lead to substantial shifts in the ecology and composition of the individual microbiome over extensive period…”
BackgroundMicrobial tryptophan catabolites in health and disease
Roager, H. M., & Licht, T. R. (2018) · Nature Communications · doi:10.1038/s41467-018-05470-4 · Cited by 2,236 · cited 1×
“Numerous bacteria including species of Bacteroides, Clostridium, Lactobacillus, Peptostreptococcus, Bifidobacterium and Ruminococcus have been demonstrated to be involved in the degradation of tryptophan into several catabolites [39].”
BackgroundThe Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Rothhammer, V., Mascanfroni, I. D., Bunse, L., Takenaka, M. C., Kenison, J. E., Mayo, L., Chao, C.-C., Patel, B., Yan, R., Blain, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4106 · Cited by 1,559
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“Recently, several studies suggested the role of the GM in modulating patient response to immunotherapy in cancer [16,17,36,62,63].”
BackgroundRaman, M., Ahmed, I., Gillevet, P. M., Probert, C. S., Ratcliffe, N. M., Smith, S., Greenwood, R., Sikaroodi, M., Lam, V., Crotty, P., et al. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.015 · Cited by 672 · cited 1×
“Indeed, amongst VOCs identified in stool samples, metabolites like terpenes (g-terpinene and 3-carene) showed a statistical significance even though they might not be directly correlated with the condition as they originate from dietary sources (fruits and vegetables) [31].”
BackgroundThe role of the microbiome in cancer development and therapy
Bhatt, A. P., Redinbo, M. R., & Bultman, S. J. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21398 · Cited by 653 · cited 1×
“In humans, studies on cancer patients undergoing immunotherapy revealed a higher microbial diversity correlated with improved survival rates [12,13].”
BackgroundJin, Y., Dong, H., Xia, L., Yang, Y., Zhu, Y., Shen, Y., Zheng, H., Yao, C., Wang, Y., & Lu, S. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.007 · Cited by 573
Microbiome and Anticancer Immunosurveillance
Zitvogel, L., Ayyoub, M., Routy, B., & Kroemer, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.001 · Cited by 478
Gut Microbiota Profiling: Metabolomics Based Approach to Unravel Compounds Affecting Human Health
Vernocchi, P., Del Chierico, F., & Putignani, L. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01144 · Cited by 426
Self-citationCarter, S. L., Brechbühler, C. M., Griffin, M., & Bond, A. T. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth234 · Cited by 344
Towards microbial fermentation metabolites as markers for health benefits of prebiotics
Verbeke, K. A., Boobis, A. R., Chiodini, A., Edwards, C. A., Franck, A., Kleerebezem, M., Nauta, A., Raes, J., van Tol, E. A. F., & Tuohy, K. M. (2015) · Nutrition Research Reviews · doi:10.1017/s0954422415000037 · Cited by 343 · cited 1×
“Moreover, they represent beneficial products derived from both proteolytic and saccharolytic fermentation [25] used not only as an energy source for the host’s colonocytes, but also for their anti-inflammatory properties [26,27].”
BackgroundHakozaki, T., Richard, C., Elkrief, A., Hosomi, Y., Benlaïfaoui, M., Mimpen, I., Terrisse, S., Derosa, L., Zitvogel, L., Routy, B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0196 · Cited by 316
The production of p-cresol sulfate and indoxyl sulfate in vegetarians versus omnivores
Patel, K. P., Luo, F. J.-G., Plummer, N. S., Hostetter, T. H., & Meyer, T. W. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12491211 · Cited by 226
Botticelli, A., Vernocchi, P., Marini, F., Quagliariello, A., Cerbelli, B., Reddel, S., Del Chierico, F., Di Pietro, F., Giusti, R., Tomassini, A., et al. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02231-0 · Cited by 209 · cited 10×
“In particular, we defined non-responder (NR) patients experiencing disease progression within three months from the beginning of nivolumab [17].”
BackgroundMethodResultInfluentialSelf-citationMicrobiota effects on cancer: From risks to therapies
Rea, D., Coppola, G., Palma, G., Barbieri, A., Luciano, A., Del Prete, P., Rossetti, S., Berretta, M., Facchini, G., Perdonà, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24681 · Cited by 208 · cited 1×
“Thus, GM is considered integral in the development of different cancers such as colorectal, hepatocellular and breast cancer [3].”
BackgroundGut microbiome and anticancer immune response: really hot Sh*t!
Viaud, S., Daillère, R., Boneca, I. G., Lepage, P., Langella, P., Chamaillard, M., Pittet, M. J., Ghiringhelli, F., Trinchieri, G., Goldszmid, R., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.56 · Cited by 123
Jeong, J.-J., Kim, K.-A., Jang, S.-E., Woo, J.-Y., Han, M. J., & Kim, D.-H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116533 · Cited by 86
Cited by
The Role of Gut Microbiota in Lung Cancer: From Carcinogenesis to Immunotherapy
(2021) · doi:10.3389/fonc.2021.720842 · Cited by 136
Role of gut microbes in acute lung injury/acute respiratory distress syndrome
Ren, Z., Zheng, Z., & Feng, X. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2440125 · Cited by 48
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
Gut microbiota and SCFAs improve the treatment efficacy of chemotherapy and immunotherapy in NSCLC
Yang, Y., Ye, M., Song, Y., Xing, W., Zhao, X., Li, Y., Shen, J., Zhou, J., Arikawa, K., Wu, S., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00785-9 · Cited by 36
Metadata
- Authors
- Vernocchi, P., Gili, T., Conte, F., Del Chierico, F., Conta, G., Miccheli, A., Botticelli, A., Paci, P., Caldarelli, G., Nuti, M., Marchetti, P., & Putignani, L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-11-19
- Volume
- 21
- Issue
- 22
- Pages
- 8730
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3104428311
- Cited by
- 148
- References
- 30
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.